Blog

Dosimetry tells you the dose. It doesn’t tell you the decision.

Learn why absorbed dose data alone isn't enough for radiopharmaceutical dose optimization, and how BED,…

CertaraJuly 7, 2026

Blog

Enhancing clinical trials with real-world evidence in pregnancy research

Learn how real-world evidence improves clinical trials in pregnancy by enhancing safety data, trial design,…

CertaraJune 26, 2026

Poster

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Discover how endogenous ligand competition was incorporated into a whole-body PBPK model to improve prediction…

CertaraJune 23, 2026

Poster

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Learn how Certara's IO Simulator was used to predict efficacy, cytokine release syndrome risk, and…

CertaraJune 23, 2026

Poster

Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab

Discover how Quantitative Systems Pharmacology (QSP) was used to predict cytokine release syndrome risk and…

CertaraJune 23, 2026

Poster

Mechanistic QSP Modeling to Support KIT Inhibitor Dose Selection, Biomarker Strategy, and Clinical Development

Discover how a mechanistic quantitative systems pharmacology (QSP) model predicts mast cell inhibition and depletion…

CertaraJune 16, 2026

Poster

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.

CertaraJune 9, 2026

Publication

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…

Dorottya Gui-BodnarMay 28, 2026

Publication

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models

This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…

CertaraMay 21, 2026

Publication

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…

CertaraMay 7, 2026

Therapeutic Specialties

Dosimetry tells you the dose. It doesn’t tell you the decision.

Enhancing clinical trials with real-world evidence in pregnancy research

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab

Mechanistic QSP Modeling to Support KIT Inhibitor Dose Selection, Biomarker Strategy, and Clinical Development

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

Newsletter sign up

Quick links

Solutions

Contact